




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07D 451/04, 453/02, 498/08		A1	(11) International Publication Number: WO 92/11259
(21) International Application Number: PCT/GB91/02210		(43) International Publication Date: 9 July 1992 (09.07.92)	
(22) International Filing Date: 12 December 1991 (12.12.91)		(74) Agent: JONES, Pauline; SmithKline Beecham, Corporate Patents, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB).	
(30) Priority data: 9027487.9 19 December 1990 (19.12.90) GB		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), MC (European patent), NL (European patent), SE (European patent), US.	
(71) Applicant (for all designated States except US): BEECHAM GROUP PLC [GB/GB]; Four New Horizons Court, Harlequin Avenue, Brentford, Middlesex TW8 9EP (GB).		Published With international search report.	
(72) Inventor; and (75) Inventor/Applicant (for US only) : KING, Francis, David [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB).			

(54) Title: AZABICYCLIC AMIDES OR ESTERS OF HALOGENATED BENZOIC ACIDS



(57) Abstract

Compounds of formula (I) wherein Z is a di-azacyclic or azabicyclic side chain having 5-HT₃ receptor antagonist activity.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brasil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CC	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU+	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America

+ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

AZABICYCLIC AMIDES OR ESTERS OF HALOGENATED BENZOIC ACIDS

This invention relates to novel compounds having pharmacological activity, to a process for their preparation and their use as pharmaceuticals.


EP-A-220011 (Beecham Group p.l.c.) describes the use of a benzamide derivative, as a 5-HT₃ receptor antagonist.

10 A group of novel compounds has now been discovered, which compounds are 5-HT₃ receptor antagonists.

Accordingly, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof:

15

20



wherein

R₁ is hydrogen or C₁₋₆ alkoxy;

25 R₂ is halo;

R₃ is halo;

L is O or NH; and

Z is a di-azacyclic or azabicyclic side chain;
having 5-HT₃ receptor antagonist activity.

30

Suitable examples of alkyl moieties in R₁ include methyl, ethyl, n- and iso-propyl, n-, iso-, sec- and tert-butyl.

-2-

Suitable examples of halo moieties include fluoro, chloro and bromo.

5 In particular, R₁ is hydrogen, R₂ is chloro and R₃ is chloro; or R₁ is methoxy, R₂ is fluoro or chloro and R₃ is chloro.


Suitable examples of Z are described in the art relating to
10 5-HT₃ receptor antagonists, ie. as follows:

- i) GB 2125398A (Sandoz Limited)
- ii) GB 2152049A (Sandoz Limited)
- iii) EP-A-215545 (Beecham Group p.l.c.)
- 15 iv) EP-A-214772 (Beecham Group p.l.c.)
- v) EP-A-377967 (Beecham Group p.l.c.)
- vi) PCT/GB91/01629 (Beecham Group p.l.c.)
- vii) EP-A-358903 (Dianippon)

20 Particular side chains of interest are depicted thus:

Tropane


25



Granatane

30


35




-3-

Oxa/thia-granatane

5

Quinuclidine


10

Isoquinuclidine


20

Isogranatane

25

Oxa/thia-isogranatane


30



-4-

Isotropane

5



or



wherein

R is hydrogen or methyl; and X is oxygen, sulphur or
10 nitrogen optionally substituted by C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₃₋₈ cycloalkyl C₁₋₄ alkyl, phenyl, naphthyl, phenyl C₁₋₄ alkyl or naphthyl C₁₋₄ alkyl wherein a phenyl or naphthyl moiety is optionally substituted by one or more of halo, C₁₋₆ alkoxy or C₁₋₆ alkyl.

15

Side chains Z of particular interest include tropane, oxagranatane and azagranatane, where R is methyl. Suitable values for N-substituents when X is N are as described in PCT/GB91/01629, for example, iso-propyl or ethyl.

20

Z is preferably NH.

Alternatively, COL in formula (I) may be replaced by a bioisostere therefor, for example, 1,2,4-oxadiazole and the 25 other groups of structure h) described in EP-A-377967 (Beecham Group p.l.c.).

The pharmaceutically acceptable salts of the compounds of the formula (I) include acid addition salts with 30 conventional acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric acids and pharmaceutically acceptable organic acids such as acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, α -keto glutaric, α -glycerophosphoric, and glucose-1-phosphoric 35 acids.

-5-

Examples of pharmaceutically acceptable salts include quaternary derivatives of the compounds of formula (I) such as the compounds quaternised by compounds R_x -T wherein R_x is C_{1-6} alkyl, phenyl- C_{1-6} alkyl or C_{5-7} cycloalkyl, and T is a radical corresponding to an anion of an acid. Suitable examples of R_x include methyl, ethyl and n- and iso-propyl; and benzyl and phenethyl. Suitable examples of T include halide such as chloride, bromide and iodide.


10 Examples of pharmaceutically acceptable salts also include internal salts such as N-oxides.

The compounds of the formula (I), their pharmaceutically acceptable salts, (including quaternary derivatives and 15 N-oxides) may also form pharmaceutically acceptable solvates, such as hydrates, which are included wherever a compound of formula (I) or a salt thereof is herein referred to.

20 It will of course be realised that some of the compounds of the formula (I) have chiral or prochiral centres and thus are capable of existing in a number of stereoisomeric forms including enantiomers. The invention extends to each of these stereoisomeric forms (including enantiomers), and to 25 mixtures thereof (including racemates). The different stereoisomeric forms may be separated one from the other by the usual methods.

The invention also provides a process for the preparation of 30 a compound of formula (I), or a pharmaceutically acceptable salt thereof, which process comprises reacting a compound of formula (II):

35



-6-

with a compound of formula (III):

HLZ'

(III)

5 or a reactive derivative thereof, when L is O;

wherein R₁', R₂', R₃' and/or Z' are R₁, R₂, R₃ and/or Z respectively or groups or atoms convertible thereto; R₄ is hydrogen or an N-protecting group; Q₁ is a leaving group; 10 and the remaining variables are as hereinbefore defined; and thereafter optionally converting R₁', R₂', R₃' and/or Z' to another group or atom R₁, R₂, R₃ or Z; and optionally forming a pharmaceutically acceptable salt of the resultant compound of formula (I).

15

Examples of R₄, when other than hydrogen, include C₁₋₁₀ acyl such as C₁₋₇ alkanoyl, wherein the alkyl may be as listed for R₁, preferably acetyl.

R₄ is usually hydrogen.

20

Examples of leaving groups Q₁, displaceable by a nucleophile, include halogen such as chloro and bromo, hydroxy, C₁₋₄ alkoxy, such as CH₃O and C₂H₅O-, PhO-, activated hydrocarbyloxy, such as Cl₅C₆O- or Cl₃CO-; or 25 COQ₁, forms a mixed anhydride, so that Q₁ is carboxylic acyloxy; or a nitrogen-linked heterocycle, such as imidazole.

If a group Q₁ is a halide, or COQ₁, forms a mixed anhydride, 30 then the reaction is preferably carried out at non-extreme temperatures in an inert non-hydroxylic solvent, such as benzene, dichloromethane, toluene, diethyl ether, tetrahydrofuran (THF) or dimethylformamide (DMF). It is also preferably carried out in the presence of an acid acceptor, such as an organic base, in particular a tertiary amine, such as triethylamine, trimethylamine, pyridine or

-7-

picoline, some of which can also function as the solvent. Alternatively, the acid acceptor can be inorganic, such as calcium carbonate, sodium carbonate or potassium carbonate. Temperatures of 0°-100°C, in particular 10-80°C are 5 suitable.

If a group Q₁ is C₁₋₄ alkoxy, phenoxy or activated hydrocarbyloxy then the reaction is preferably carried out in an inert polar solvent, such as toluene or 10 dimethylformamide. It is also preferred that the group Q₁ is Cl₃CO- and that the reaction is carried out in toluene at reflux temperature.

If a group Q₁ is hydroxy, then the reaction is generally 15 carried out in an inert non-hydroxylic solvent, such as dichloromethane, THF or DMF optionally in the presence of a dehydrating agent such as a carbodiimide, for example dicyclohexylcarbodiimide. The reaction may be carried out at any non-extreme temperature, such as -10 to 100°C, for 20 example, 0 to 80°C. Generally, higher reaction temperatures are employed with less active compounds whereas lower temperatures are employed with the more active compounds.

If a group Q₁ is carboxylic acyloxy, then the reaction is 25 preferably carried in substantially the same manner as the reaction when Q₁ is halide. Suitable examples of acyloxy leaving groups include C₁₋₄ alkanoyloxy and C₁₋₄ alkoxycarbonyloxy, in which case the reaction is preferably carried out in an inert solvent, such as dichloromethane, at 30 a non-extreme temperature for example ambient temperatures in the presence of an acid acceptor, such as triethylamine. C₁₋₄ alkoxycarbonyloxy leaving groups may be generated in situ by treatment of the corresponding compound wherein Q₁ is hydroxy with a C₁₋₄ alkyl chloroformate.

-8-

If a group Q_1 is activated hydrocarbyloxy then the reaction is preferably carried out in an inert polar solvent, such as dimethylformamide. It is also preferred that the activated hydrocarbyloxy group is a pentachlorophenyl ester and that the reaction is carried out at ambient temperature.

When Y is O the compound of formula (III) may be in the form of a reactive derivative thereof, which is often a salt, such as the lithium, sodium or potassium salt.

10

An R_2' or R_3' group which is convertible to R_2 or R_3 include a hydrogen substituent which is convertible to a halogen substituent by halogenation using conventional halogenating agents.

15

Z' when other than Z may be wherein R is replaced by R' which is a hydrogenolysable protecting group which is benzyl optionally substituted by one or two groups selected from halo, C_{1-4} alkoxy and C_{1-4} alkyl. Such benzyl groups may, 20 for example, be removed, when R_1/R_2 is not halogen, by conventional transition metal catalysed hydrogenolysis to give compounds of the formula (I) wherein R is hydrogen.

This invention also provides a further process for the 25 preparation of a compound of the formula (I) wherein R is methyl or a pharmaceutically acceptable salt thereof, which comprises N-methylating a compound of formula (I) wherein R is hydrogen, and optionally forming a pharmaceutically acceptable salt of the resulting compound of the formula 30 (I). In this further process of the invention 'N-methylation' may be achieved by reaction with a compound CH_3Q_2 wherein Q_2 is a leaving group.

Suitable values for Q_2 include groups displaced by 35 nucleophils such as Cl, Br, I, OSO_2CH_3 or $OSO_2C_6H_4PCH_3$.

-9-

preferably Cl, Br or I.

The reaction may be carried out under conventional alkylation conditions for example in an inert solvent such as dimethylformamide in the presence of an acid acceptor such as potassium carbonate. Generally the reaction is carried out at non-extreme temperature such as at ambient or slightly above.

Alternatively, 'N-methylation' may be effected under conventional reductive alkylation conditions.

Interconverting R in the compound of the formula (III) before coupling with the compound of the formula (II) is also possible. Such interconversions are effected conveniently under the above conditions. It is desirable to protect any amine function with a group readily removable by acidolysis such as a C₂-7 alkanoyl group, before R/Z interconversion.

It is often convenient in the preparation of such a compound of formula (III) to prepare the corresponding compound wherein the methyl group is replaced by alkoxycarbonyl. Such compounds may then be reduced using a strong reductant such as lithium aluminium hydride to the corresponding compound of formula (II).

The benzoic acid derivative intermediates of formula (II) are known or are preparable analogously to, or routinely from, known compounds. When R₂ is fluoro, the intermediate may be prepared by fluorination of the corresponding R₂ is hydrogen compound, using a suitable fluorinating catalyst, such as trifluoromethyl hypofluorite, as described in Description 1 hereinafter.

35

Compounds of the formula (III) are generally prepared from the corresponding exocyclic keto derivative of the

-10-

azabicyclic side chain, prepared by condensation methods, often using a substituted piperidine. They may be prepared by processes described in the aforementioned Patent Publications relating to values of the side chain Z.

5

It will be realised that in the compounds of the formula (I) having a tropane, granatane or oxa/thia/aza-granatane side chain, the -COL- linkage has an **endo** orientation with respect to the ring of the bicyclic moiety to which it is attached. A mixture of **endo** and **exo** isomers of the compound of the formula (I) may be synthesised non-stereospecifically and the desired isomer separated conventionally therefrom e.g. by chromatography; or alternatively the **endo** isomer may if desired be synthesised from the corresponding **endo** form 15 of the compound of the formula (II). Corresponding geometric isomeric pairs are possible for the isoquinuclidine, isogranatane, oxa/thia-isogranatane and isotropane side chains.

20 Pharmaceutically acceptable salts of the compounds of this invention may be formed conventionally.

The salts may be formed for example by reaction of the base compound of formula (I) with a pharmaceutically acceptable 25 organic or inorganic acid.

The compounds of the present invention are 5-HT₃ receptor antagonists and it is thus believed may generally be used in the treatment or prophylaxis of pain, emesis, CNS disorders 30 and gastrointestinal disorders. Pain includes migraine, cluster headache, trigeminal neuralgia and visceral pain; emesis, includes, in particular, that of preventing vomiting and nausea associated with cancer therapy, post-operative 35 emesis, and nausea associated with migraine. Examples of such cancer therapy include that using cytotoxic agents, such as platinum complexes including cisplatin, and also

-11-

doxorubicin and cyclophosphamide, particularly cisplatin; and also radiation treatment. CNS disorders include anxiety, psychosis, cognitive disorders such as senile dementia and age associated memory impairment (AAMI), and 5 drug dependence. Gastrointestinal disorders include irritable bowel syndrome and diarrhoea.

5-HT₃ receptor antagonists may also be of potential use in the treatment of obesity, arrhythmia, and/or disorders 10 associated with myocardial instability.

The invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable 15 carrier.

Such compositions are prepared by admixture and are usually adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid 20 preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusible solutions or suspensions or suppositories. Orally administrable compositions are preferred, since they are more convenient for general use.

25 Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated 30 according to well known methods in the art, for example with an enteric coating.

Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants 35 include starch, polyvinylpolypyrrolidone and starch

-12-

derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate.

Suitable pharmaceutically acceptable wetting agents include 5 sodium lauryl sulphate. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations 10 may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan 15 monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, 20 and if desired conventional flavouring or colouring agents.

Oral liquid preparations are usually in the form of aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs or are presented as a dry product for reconstitution 25 with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and flavouring or colouring agents.

30

The oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large 35 quantities of fillers. Such operations are, of course,

-13-

conventional in the art.

For parenteral administration, fluid unit dose forms are prepared containing a compound of the present invention and 5 a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.

10 Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.

15

Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure of ethylene oxide before suspending in the sterile 20 vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.

The invention further provides a method of treatment or 25 prophylaxis of pain, emesis, CNS disorders and/or gastrointestinal disorders in mammals, such as humans, which comprises the administration of an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.

30

An amount effective to treat the disorders herein- before described depends on the relative efficacies of the compounds of the invention, the nature and severity of the disorder being treated and the weight of the mammal.

35 However, a unit dose for a 70kg adult will normally contain 0.05 to 1000mg for example 0.5 to 500mg, of the compound of the invention. Unit doses may be administered once or more

-14-

than once a day, for example, 2, 3 or 4 times a day, more usually 1 to 3 times a day, that is in the range of approximately 0.0001 to 50mg/kg/day, more usually 0.0002 to 25 mg/kg/day.

5

No adverse toxicological effects are indicated within the aforementioned dosage ranges.

The invention also provides a compound of formula (I) or a 10 pharmaceutically acceptable salt thereof for use as an active therapeutic substance, in particular for use in the treatment of pain, emesis, CNS disorders and/or gastrointestinal disorders.

15 The following Examples illustrate the preparation of compounds of formula (I).

Examples

20

Ex. No.	R ₁	R ₂	R ₃	L	Z
1	H	Cl	Cl	NH	NmT
2	H	Cl	Cl	NH	Q
25 3	OCH ₃	Cl	Cl	NH	NmT
4	OCH ₃	Cl	Cl	NH	NmO
5	OCH ₃	F	Cl	NH	NmT

30

NmT = N-methyltropane

Q = Quinuclidin-3-yl

NmO = N-methyloxagranatane

-15-

Description

a) Methyl-4-acetamido-5-chloro-3-fluoro-2-methoxybenzoate

5 Methyl-4-acetamido-5-chloro-2-methoxy benzoate (10.9g) was dissolved in chloroform (40 ml), cooled to -10°C under nitrogen. A three molar excess of trifluoromethyl hypofluorite was slowly bubbled through the stirred, cooled solution for 6 hours. A slow positive nitrogen stream was 10 maintained throughout the reaction. After warming to room temperature and thoroughly purging with nitrogen, the chloroform was removed in *vacuo*.

The residue was chromatographed on silica using chloroform 15 with increasing amounts of methanol as eluant. The product was isolated as an off white solid.

¹H NMR (CDCl₃) 250MHz

20 δ: 7.64 (d, 1H), 7.37 (bs, 1H), 3.98 (bs, 3H), 3.9 (s, 3H), 2.2 (s, 3H)

b) 4-Amino-5-chloro-3-fluoro-2-methoxybenzoic acid

25 Methyl-4-acetamido-5-chloro-3-fluoro-2-methoxybenzoate (1.89g) in 25 ml ethanol was treated with a solution of sodium hydroxide (1.15g) in 15 ml water. The mixture was heated under reflux for 16 hours then cooled. The solvent was removed in *vacuo* and the residue acidified. The 30 precipitated solid was collected by filtration to give 1.48g product.

¹H NMR (DMSO) 250MHz


35 δ: 7.49 (d, 1H), 6.19 (bs, 1H), 3.80 (s, 3H)

-16-

Example 1endo-N-(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl)-4-amino-3,5-dichlorobenzamide (E1)

5

10



15 To a stirred solution of 4-amino-3,5-dichlorobenzoic acid (1.1g) in CH_2Cl_2 (50 ml) and Et_3N (0.8 ml) at 0°C was added EtO_2CCl (0.48 ml). After stirring to room temperature for 1h, a solution of the *endo*-8-methyl-8-azabicyclo[3.2.1]octan-3-amine (0.7 g) in CH_2Cl_2 (10 ml) was 20 added and the whole stirred overnight. The reaction mixture was washed with sat. NaHCO_3 solution, dried and evaporated. Recrystallisation of the residue (EtOAc/petrol) gave the title compound (0.35 g) mp 192-193 $^\circ\text{C}$.

25

^1H NMR (CDCl_3) δ 7.55 (s, 2H)
6.25 (brd 1H)
4.76 (brs, 2H)
4.22 (q, 1H)
3.21 (brs, 2H)
2.33 (s, 3H)
2.35-2.10 (m, 4H)
1.88-1.68 (m, 4H)

30

-17-

Prepared similarly was:

Example 2

5 N-(1-Azabicyclo[2.2.2]octan-3-yl)-4-amino-3,5-dichlorobenzamide (E2)

mp 233-235°C.

10

Example 3

endo-N-(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl)-4-amino-3,5-dichloro-2-methoxybenzamide (E3)

15

A solution of endo-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-4-amino-5-chloro-2-methoxybenzamide (0.8g) in CH₃COOH (25 mL) was treated with a solution of Cl₂ (0.18 g) in CH₃COOH (5 mL). After standing at room temperature overnight, the solvent was removed by rotary evaporation and the residue partitioned between EtOAc and aqueous NaHCO₃ solution. The organic extract was separated, dried (K₂CO₃) evaporated and the residue purified by flash chromatography (SiO₂, 5-10% MeOH/CHCl₃) to give the title compound (0.065 g) mp 148-151°C.

Prepared similarly was:

Example 4

30

endo-N-(9-Methyl-9-aza-3-azabicyclo[3.3.1]nonan-7-yl)-4-amino-3,5-dichloro-2-methoxybenzamide (E4)

mp 170-172°C.

35

-18-

Example 5

endo-4-Amino-5-chloro-3-fluoro-2-methoxy-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)benzamide (E5)

5

The title compound was prepared from 4-amino-5-chloro-3-fluoro-2-methoxybenzoic acid via an analogous procedure to that described for Example 1.

10 The product was isolated as the hydrochloride salt, mp 202-203°C.

¹H NMR (free base), (CDCl₃), 250 MHz

15 δ: 8.61 (bd, 1H), 7.81 (d, 1H), 4.34 (bs, 2H), 4.20 (dd, 1H), 3.98 (d, 3H), 3.10 (b, 2H), 1.53-2.21 (m, 11H inc.s, 2.21, 3H).

20

5-HT₃ Receptor Antagonist Activity

Compounds are evaluated for antagonism of the von Bezold-Jarisch reflex evoked by 5-HT in the anaesthetised 25 rat according to the following method:


Male rats 250-350g, are anaesthetised with urethane (1.25g/kg intraperitoneally) and blood pressure and heart rate are recorded as described by Fozard J.R. et al., J. 30 Cardiovasc. Pharmacol. 2, 229-245 (1980). A submaximal dose of 5-HT (usually 6μg/kg) is given repeatedly by the intravenous route and changes in heart rate quantified. Compounds are given intravenously and the concentration required to reduce the 5-HT-evoked response to 50% of the 35 control response (ED₅₀) is then determined.

Claims

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof:

5

10



(I)

wherein

R₁ is hydrogen or C₁₋₆ alkoxy;

15 R₂ is halo;

R₃ is halo;

L is O or NH; and

Z is a di-azacyclic or azabicyclic side chain;
having 5-HT₃ receptor antagonist activity.

20

2. A compound according to claim 1 wherein R₁ is hydrogen,
R₂ is chloro and R₃ is chloro.

3. A compound according to claim 1 wherein R₁ is methoxy,
25 R₂ is fluoro or chloro and R₃ is chloro.

4. A compound according to any one of claims 1 to 3
wherein the side chain Z is tropane, granatane,
oxa/thia/aza-granatane, quinuclidine, isoquinuclidine,
30 isogranatane, oxa/thia-isogranatane or isotropane.

5. A compound according to claim 4 wherein Z is tropane,
oxagranatane or azagranatane.

-20-

6. A compound according to any one of claims 1 to 5 wherein L is NH.

7. *endo*-N-(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl)-4-amino-3,5-dichlorobenzamide.

8. N-(1-Azabicyclo[2.2.2]octan-3-yl)-4-amino-3,5-dichlorobenzamide.

10 9. *endo*-N-(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl)-4-amino-3,5-dichloro-2-methoxybenzamide.

10. *endo*-N-(9-Methyl-9-aza-3-azabicyclo[3.3.1]nonan-7-yl)-4-amino-3,5-dichloro-2-methoxybenzamide.

15


11. *endo*-4-Amino-5-chloro-3-fluoro-2-methoxy-N-(8-methyl-8-azabicyclo[3.2.1.]octan-3-yl)benzamide.

12. A pharmaceutically acceptable salt of a compound
20 according to any one of claims 7 to 11.

13. A compound according to claim 1 substantially as defined herein with reference to the Examples.

25 14. A process for the preparation of a compound according to claim 1, which process comprises reacting a compound of formula (II):

30



with a compound of formula (III):

HLZ'

(III)

or a reactive derivative thereof, when L is O;

5

wherein R₁', R₂', R₃' and/or Z' are R₁, R₂, R₃ and/or Z respectively or groups or atoms convertible thereto; R₄ is hydrogen or an N-protecting group; Q₁ is a leaving group; and the remaining variables are as defined in claim 1; and thereafter optionally converting R₁', R₂', R₃' and/or Z' to another group or atom R₁, R₂, R₃ or Z; and optionally forming a pharmaceutically acceptable salt of the resultant compound of formula (I).

15 15. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

16. A method of treatment or prophylaxis of pain, emesis, CNS disorders and/or gastrointestinal disorders in mammals, such as humans, which comprises the administration of an effective amount of a compound according to claim 1.

17. A compound according to any one of claims 1 to 13 for use as an active therapeutic substance.

18. A compound according to any one of claims 1 to 13 for use in the treatment of pain, emesis, CNS disorders and/or gastrointestinal disorders.

30

19. The use of a compound according to any one of claims 1 to 13 in the manufacture of a medicament for the treatment and/or prophylaxis of pain, emesis, CNS disorders and/or gastrointestinal disorders.

35

INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 91/02210

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 07 D 451/04, 453/02, 498/08						
II. FIELDS SEARCHED Minimum Documentation Searched ⁷ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left; padding: 2px;">Classification System</th> <th style="text-align: left; padding: 2px;">Classification Symbols</th> </tr> </thead> <tbody> <tr> <td style="padding: 2px;">IPC5</td> <td style="padding: 2px;">C 07 D</td> </tr> </tbody> </table>			Classification System	Classification Symbols	IPC5	C 07 D
Classification System	Classification Symbols					
IPC5	C 07 D					
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched ⁸						
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹						
Category ¹⁰	Citation of Document ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³				
X	EP, A2, 0220011 (BEECHAM GROUP PLC) 29 April 1987, see compound 20 --	1-15, 17- 19				
X	EP, A2, 0377967 (BEECHAM GROUP PLC) 18 July 1990, see example 2 --	1-15, 17- 19				
X	EP, A1, 0099789 (DELALANDE S.A.) 1 February 1984, see especially compound 24 --	1-15, 17- 19				
* Special categories of cited documents: ¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family						
IV. CERTIFICATION						
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report					
10th March 1992	6.1.1992					
International Searching Authority	Signature of Authorized Officer					
EUROPEAN PATENT OFFICE	<i>Magdalé Weinholtz</i>					

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	DE, DE, 3001328 (DELALANDE S.A.) 24 July 1980, see example 74	1,4,14- 15,17- 19

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers 16, because they relate to subject matter not required to be searched by this Authority, namely:

See PCT Rule 39.1 (iv: Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

2. Claim numbers 1-4* because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

The scope of the claims 1-4, 14-15, 17-19 is so broadly formulated that a very wide range of structures is included. These claims have thus not been fully searched.

* 14-15, 17-19

3. Claim numbers....., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- The additional search fees were accompanied by applicant's protest.
 No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.PCT/GB 91/02210**

SA 53948

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 01/02/92.
The European Patent office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A2- 0220011	29/04/87	AU-D- JP-A- 6385586 62155277	16/04/87 10/07/87
EP-A2- 0377967	18/07/90	AU-D- JP-A- 4608189 2202890	21/06/90 10/08/90
EP-A1- 0099789	01/02/84	AU-B- AU-D- CA-A- FR-A-B- JP-A- US-A- 562210 1650783 1265802 2529548 59021684 4657911	04/06/87 05/01/84 13/02/90 06/01/84 03/02/84 14/04/87
DE-DE- 3001328	24/07/80	AU-B- AU-D- BE-A- CA-A- CA-A- CH-A- CH-A- FR-A-B- FR-A-B- GB-A-B- GB-A-B- JP-C- JP-A- JP-A- JP-A- JP-B- LU-A- NL-A- NL-A- SE-B-C- SE-B-C- SE-A- US-A- US-A- US-A- US-A- US-A- 542537 5461080 881134 1130286 1160227 646969 647520 2446823 2476088 2042522 2055374 1333568 55108871 56164187 59076084 60059915 82083 8000277 8005774 431984 444941 8000068 4321378 4329466 4424358 4471120 4536580	28/02/85 24/07/80 14/07/80 24/08/82 10/01/84 28/12/84 31/01/85 14/08/80 21/08/81 24/09/80 04/03/81 28/08/86 21/08/80 17/12/81 28/04/84 27/12/85 10/09/81 18/07/80 30/01/81 12/03/84 20/05/86 17/07/80 23/03/82 11/05/82 03/01/84 11/09/84 20/08/85

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

EPO FORM P0479